Literature DB >> 23422336

Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats.

Azadeh Sabetghadam1, Surash Ramanathan, Sreenivasan Sasidharan, Sharif Mahsufi Mansor.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Mitragyna speciosa is a popular medicinal plant in Southeast Asia which is commonly used for its morphine-like effects. Although the analgesic properties of Mitragyna speciosa and its ability to ameliorate withdrawal signs after abrupt cessation of opioid abuse are well known, information about the long-term safety of the plant's active compounds is lacking. In this work, we evaluated the effects of sub-chronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa leaves in rats.
MATERIALS AND METHODS: Male and female Sprague-Dawley rats received three doses of mitragynine (1, 10, 100mg/kg, p.o) for 28 days respectively. Food intake and relative body weight were measured during the experiment. After completion of drug treatment biochemical, hematological, and histological analyses were performed.
RESULTS: No mortality was observed in any of the treatment groups. The groups of rats treated with the lower and intermediate doses showed no toxic effects during the study. However, the relative body weight of the group of female rats treated with the 100mg/kg dose was decreased significantly. Food intake also tended to decrease in the same group. Only relative liver weight increased after treatment with the high dose of mitragynine (100mg/ kg) in both the male and female treatment groups of rats. Biochemical and hematological parameters were also altered especially in high dose treatment group which corresponds to the histopathological changes.
CONCLUSIONS: The study demonstrated that mitragynine is relatively safe at lower sub-chronic doses (1-10mg/kg) but exhibited toxicity at a highest dose (sub-chronic 28 days: 100mg/kg). This was confirmed by liver, kidney, and brain histopathological changes, as well as hematological and biochemical changes.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23422336     DOI: 10.1016/j.jep.2013.02.008

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  18 in total

1.  Discriminative stimulus properties of mitragynine (kratom) in rats.

Authors:  Norsyifa Harun; Zurina Hassan; Visweswaran Navaratnam; Sharif M Mansor; Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2015-01-25       Impact factor: 4.530

2.  Anxiolytic-like effects of mitragynine in the open-field and elevated plus-maze tests in rats.

Authors:  Ammar Imad Hazim; Surash Ramanathan; Suhanya Parthasarathy; Mustapha Muzaimi; Sharif Mahsufi Mansor
Journal:  J Physiol Sci       Date:  2014-01-25       Impact factor: 2.781

3.  Physiological dependence to mitragynine indicated by a rapid cross-dependence procedure with heroin-dependent mice.

Authors:  Kai Yue; Jonathan L Katz; Xiji Shu
Journal:  Psychopharmacology (Berl)       Date:  2022-02-02       Impact factor: 4.530

Review 4.  Kratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review.

Authors:  Jonathan Schimmel; Richard C Dart
Journal:  Drugs       Date:  2020-02       Impact factor: 11.431

5.  Subchronic toxicity study of standardized methanolic extract of Mitragyna speciosa Korth in Sprague-Dawley Rats.

Authors:  Mohd U Ilmie; Hasnan Jaafar; Sharif M Mansor; Jafri M Abdullah
Journal:  Front Neurosci       Date:  2015-06-17       Impact factor: 4.677

Review 6.  Hepatotoxicity Induced by "the 3Ks": Kava, Kratom and Khat.

Authors:  Flaminia Pantano; Roberta Tittarelli; Giulio Mannocchi; Simona Zaami; Serafino Ricci; Raffaele Giorgetti; Daniela Terranova; Francesco P Busardò; Enrico Marinelli
Journal:  Int J Mol Sci       Date:  2016-04-16       Impact factor: 5.923

Review 7.  Biochemical Benefits, Diagnosis, and Clinical Risks Evaluation of Kratom.

Authors:  Dimy Fluyau; Neelambika Revadigar
Journal:  Front Psychiatry       Date:  2017-04-24       Impact factor: 4.157

Review 8.  The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.

Authors:  Jack E Henningfield; Reginald V Fant; Daniel W Wang
Journal:  Psychopharmacology (Berl)       Date:  2017-12-23       Impact factor: 4.530

9.  Kratom: a dangerous player in the opioid crisis.

Authors:  Khadija Tayabali; Colin Bolzon; Paul Foster; Janki Patel; Mohammad Omar Kalim
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-06-12

Review 10.  Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries.

Authors:  Eduardo Cinosi; Giovanni Martinotti; Pierluigi Simonato; Darshan Singh; Zsolt Demetrovics; Andres Roman-Urrestarazu; Francesco Saverio Bersani; Balasingam Vicknasingam; Giulia Piazzon; Jih-Heng Li; Wen-Jing Yu; Máté Kapitány-Fövény; Judit Farkas; Massimo Di Giannantonio; Ornella Corazza
Journal:  Biomed Res Int       Date:  2015-11-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.